Robert J. Motzer, MD, discusses the significance of the belzutifan plus lenvatinib approval, adverse event management with the combination, and the evolving role of HIF-2α inhibition in ccRCC.
|Videos|July 5, 2022
Dr. Brugarolas on rationale for targeting HIF2α in renal cell carcinoma
Author(s)Urology Times staff
“One of the processes that is regulated by HIF2α is angiogenesis,” says James Brugarolas, MD, PhD.
Advertisement
James Brugarolas, MD, PhD, director of the Kidney Cancer Program at Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, discusses the rationale for developing therapies for renal cell carcinoma that target HIF2α.
Advertisement
Related to this article
The approval is supported by data from the phase 3 LITESPARK-011 trial.
Advertisement
Advertisement
Trending on Urology Times
1
John Sfakianos, MD, on integrating ctDNA into bladder cancer trials
2
AMA issues Category I CPT codes for implantable tibial neuromodulation in UUI
3
FDA updates in urology: September 2026
4
Enzalutamide plus salvage radiotherapy associated with improved PFS in high-risk BCR
5